Clinical Trials
29 trialsNCT07222800 2026-06-04
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT07284849 2026-06-01
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT06997497 2026-05-29
KANDLELIT-012
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04793958 2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT02448173 2026-02-02
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Vaccinogen Inc
Phase 3 Not yet recruiting
NCT05855200 2026-01-23
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline
Phase 3 Recruiting
NCT06686576 2025-12-18
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT06910514 2025-04-09
Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions
Nakafarma S.L.
Phase 3 Completed
NCT04322539 2025-04-04
FRESCO-2
Hutchmed
Phase 3 Completed
NCT05709249 2024-12-30
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Jiangsu Famous Medical Technology Co., Ltd.
Phase 3 Recruiting
NCT03750786 2023-10-26
AGENT
Isofol Medical AB
Phase 3 Completed
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT00056459 2020-02-10
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
Novartis
Phase 3 Completed
NCT02254486 2018-05-15
NOCT
Norgine
Phase 3 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT00056446 2017-03-06
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
Novartis
Phase 3 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT01410955 2014-01-23
Prevention of Irinotecan Induced Diarrhea by Probiotics
Monsea Ltd.
Phase 3 Completed
NCT00756548 2013-12-27
BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Braintree Laboratories
Phase 3 Completed
NCT00112918 2013-08-27
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00756977 2013-08-15
BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Braintree Laboratories
Phase 3 Completed
NCT00004252 2012-09-11
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Pfizer
Phase 3 Completed
NCT00026273 2012-08-07
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
Pfizer
Phase 3 Completed
NCT00006269 2012-05-25
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Novartis
Phase 3 Terminated
NCT00195585 2009-08-13
Study Evaluating Isovorin in Colon Cancer
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Completed
NCT00275210 2009-04-20
MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
Sanofi
Phase 3 Completed
NCT00337389 2007-11-19
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
Mast Therapeutics, Inc.
Phase 3 Unknown